19 results
Thumbnail

- D1.532 - Phenotypic and Functional Comparison of LAD2, HMC-1.2, and Primary Human Mast Cells

Thumbnail

- D1.530 - Patient Experience of Most Burdensome Nonadvanced Systemic Mastocytosis Symptoms From the Pivotal Summit Trial of Bezuclastinib

Thumbnail

- D1.531 - Avapritinib in Indolent Systemic Mastocytosis: Real-world Data from a Greek Case Series

Thumbnail

- D1.533 - Systemic mastocytosis despite normal baseline tryptase: a diagnostic pitfall in recurrent life-threatening anaphylaxis

Thumbnail

D2.114 - Occupational asthma and rhinitis in a worker in the single-use food packaging industry: challenges of multi-agent exposure

Thumbnail

D2.115 - Occupational asthma and rhinitis to isocyanates in industrial settings

Thumbnail

D2.108 - Type 2 Inflammation Biomarkers in Patients with Chronic Rhinosinusitis with Nasal Polyps Under Treatment with Biologic Agents

Thumbnail

D2.110 - Real-world evaluation of tezepelumab in patients with severe asthma and chronic rhinosinusitis in France: preliminary results from the ROSE retrospective study

Thumbnail

D2.113 - Comparison of Non-Asthmatic Allergic Rhinitis Patients with Normal and Low FEF25–75 Levels

Thumbnail

D2.120 - Missing the Red Flags? Identification of High-Risk Paediatric Asthma Admissions Following the 2024 BTS/NICE/SIGN Update

Thumbnail

D2.121 - Seroprotection to influenza virus in vaccinated patients with bronchial asthma on biological treatment

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child

Thumbnail

D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD

Thumbnail

D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis